Literature DB >> 28976021

Long-term liver stiffness assessment in hepatitis C virus patients undergoing antiviral therapy: Results from a 5-year cohort study.

Antonio Facciorusso1, Valentina Del Prete1, Antonio Turco1, Rosario Vincenzo Buccino1, Maurizio Cosimo Nacchiero1, Nicola Muscatiello1.   

Abstract

BACKGROUND AND AIM: Observational studies showed significant liver stiffness regression after sustained virological response, but long-term effects of antiviral therapy are still unknown. The aim of this study was to assess the magnitude of change in stiffness up to 5 years after therapy in hepatitis C patients undergoing antiviral treatment.
METHODS: Data of 153 patients were retrieved. Stiffness was assessed by Fibroscan at baseline, end of treatment, 6 months after treatment, and every year hereafter up to 5 years.
RESULTS: Seventy patients were treated with interferon-based regimens and 83 with direct antiviral agents. Baseline cirrhosis was diagnosed in 53 (34.6%) patients. Sustained virological response was achieved in 112 patients, whereas 41 were non-responders. In responders, stiffness decreased from 12.3 kPa (9-17.8) to 6.6 kPa (5.3-7.4) at 5 years. A sharper decline was observed immediately after treatment (-2.5 kPa at the end of treatment and -3.7 kPa at 6 months), while from 1 year onwards, the magnitude of stiffness decrease was progressively lower. In non-responders, stiffness showed a slight decrease at the end of treatment (from 19.2 to 18.1 kPa), then returned to baseline levels at 6 months (19.4 kPa), and finally increased over time up to 23.7 kPa (15-32.5) at 5 years. The proportion of cirrhotic patients decreased by 50% at 6 months and finally fell < 5% at 4 years after treatment.
CONCLUSIONS: Stiffness declines significantly after achieving response, and the magnitude of decline is greater in the first year after treatment, while it tends to plateau from 1 year onwards.
© 2017 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  DAA; LSM; SVR; fibrosis; interferon

Mesh:

Substances:

Year:  2018        PMID: 28976021     DOI: 10.1111/jgh.14008

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  21 in total

1.  Care of Patients Following Cure of Hepatitis C Virus Infection.

Authors:  Norah A Terrault
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-11

2.  Testosterone in Men With Chronic Hepatitis C Infection and After Hepatitis C Viral Clearance.

Authors:  Chloe S Chaudhury; Thomas Mee; Cheryl Chairez; Mary McLaughlin; Rachel Silk; Chloe Gross; Sarah Kattakuzhy; Elana Rosenthal; Shyam Kottilil; Takara L Stanley; Colleen Hadigan
Journal:  Clin Infect Dis       Date:  2019-08-01       Impact factor: 9.079

3.  Post-treatment fibrotic modifications overwhelm pretreatment liver fibrosis in predicting HCC in CHC patients with curative antivirals.

Authors:  Chung-Feng Huang; Ming-Lun Yeh; Ching-I Huang; Po-Cheng Liang; Yi-Hung Lin; Zu-Yau Lin; Shinn-Cherng Chen; Jee-Fu Huang; Chia-Yen Dai; Wan-Long Chuang; Ming-Lung Yu
Journal:  Hepatol Int       Date:  2018-11-13       Impact factor: 6.047

4.  Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?

Authors:  Nadine Kronfli; Jim Young; Shouao Wang; Joseph Cox; Sharon Walmsley; Mark Hull; Curtis Cooper; Valerie Martel-Laferriere; Alexander Wong; Neora Pick; Marina B Klein
Journal:  Clin Infect Dis       Date:  2021-08-02       Impact factor: 9.079

5.  Long-term changes in hepatic fibrosis following hepatitis C viral clearance in patients with and without HIV.

Authors:  Julia B Balmaceda; Julia Aepfelbacher; Olivia Belliveau; Chloe S Chaudhury; Cheryl Chairez; Mary McLaughlin; Rachel Silk; Chloe Gross; Sarah Kattakuzhy; Elana Rosenthal; Shyam Kottilil; David E Kleiner; Colleen Hadigan
Journal:  Antivir Ther       Date:  2019

Review 6.  Hepatitis C Virus in the Elderly in the Direct-Acting Antiviral Era: from Diagnosis to Cure.

Authors:  Mubeen Khan Mohammed Abdul; Heather S Snyder; Mythili Chunduru; Susan M K Lee; Sanjaya K Satapathy
Journal:  Curr Treat Options Infect Dis       Date:  2020-08-11

Review 7.  Integrated stress response in hepatitis C promotes Nrf2-related chaperone-mediated autophagy: A novel mechanism for host-microbe survival and HCC development in liver cirrhosis.

Authors:  Srikanta Dash; Yucel Aydin; Tong Wu
Journal:  Semin Cell Dev Biol       Date:  2019-08-08       Impact factor: 7.727

8.  Noninvasive Measurements Predict Liver Fibrosis Well in Hepatitis C Virus Patients After Direct-Acting Antiviral Therapy.

Authors:  Rui Huang; Huiying Rao; Ming Yang; Yinghui Gao; Jian Wang; Qian Jin; Danli Ma; Lai Wei
Journal:  Dig Dis Sci       Date:  2019-10-25       Impact factor: 3.199

9.  Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors.

Authors:  Patrizia Carrieri; Fabrice Carrat; Vincent Di Beo; Marc Bourlière; Tangui Barré; Victor De Ledinghen; Georges-Philippe Pageaux; Morgane Bureau; Carole Cagnot; Céline Dorival; Elisabeth Delarocque-Astagneau; Fabienne Marcellin; Stanislas Pol; Hélène Fontaine; Camelia Protopopescu
Journal:  JHEP Rep       Date:  2022-03-30

10.  Restoring Inflammatory Mediator Balance after Sofosbuvir-Induced Viral Clearance in Patients with Chronic Hepatitis C.

Authors:  Geórgia Nascimento Saraiva; Natalia Fonseca do Rosário; Thalia Medeiros; Paulo Emílio Côrrea Leite; Gilmar de Souza Lacerda; Thaís Guaraná de Andrade; Elzinandes Leal de Azeredo; Petronela Ancuta; Jorge Reis Almeida; Analúcia Rampazzo Xavier; Andrea Alice Silva
Journal:  Mediators Inflamm       Date:  2018-05-27       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.